US 8,940,522 B2Granted

Optical detector for use in therapy

AssigneeMedtronic, Inc.

InventorsOrhan Soykan, Maura G. Donovan, Amy E. Thompson

Life of this patent

Estimating the term…

Loading patent…

Abstract

Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes—a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength. The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy at the second and third wavelengths.

Claims10

Dependent claims

A method of delivering a therapy using an implantable medical device, comprising:

presenting a tagged substrate into a bodily fluid, wherein the bodily fluid is blood, wherein the bodily fluid contains an enzyme and a protein substrate, and wherein presenting the tagged substrate to the bodily fluid comprises controlling a substrate pump to present the tagged substrate to the blood via a catheter with a distal end located in a blood vessel of a patient, and further wherein the tagged substrate is tagged with at least two fluorescent dyes;
emitting energy at a first wavelength into the bodily fluid that contains the enzyme and the protein substrate, and into which the substrate tagged with the at least two fluorescent dyes has been presented;
detecting energy emitted by a first one of the dyes at a second wavelength based on fluorescent resonant energy transfer from a second one of the dyes in response to the emitted energy at the first wavelength;
and
providing a therapy device comprising a therapy pump configured to deliver a therapy based on the detected energy.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application: 13/214,860Filed 22 Aug 2011 · continuation
Priority: 25 Apr 2003
Published: US 2012/0046642 A123 Feb 2012
Granted: 27 Jan 2015
Term ends: Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61B 5/14546
Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g.…: for…
A61B 5/0071
Using light, e.g. diagnosis by transillumination, diascopy, fluorescence: by measuring fluorescence emission
A61B 5/0075
Using light, e.g. diagnosis by transillumination, diascopy, fluorescence: by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy,…
A61B 5/0084
Adapted for particular medical purposes: for introduction into the body, e.g. by catheters

Family

Application10/423,112Parent of this division · filed 25 Apr 2003
Application12/127,908Parent of this continuation · filed 28 May 2008
US 2012/0046642 A1Pre-grant publication · published 23 Feb 2012
US 8,003,373 B2Parent of this continuation
US 7,473,548 B2Parent of this division
Application12/127,908Parent of this division
US 2004/0215134 A1Published application
US 2008/0227083 A1Published application
US 8,940,522 B2This patent

From the US filing history. Foreign family members aren’t listed.